Springworks Therapeutics, INC DEF 14A proxy statements

SpringWorks Therapeutics, Inc. announced that the Bundeskartellamt approval and the HSR Act waiting period expiration, two critical conditions for its merger with Merck KGaA, have been satisfied, moving the acquisition closer to its expected consummation in the second half of 2025.

SpringWorks Therapeutics, Inc. has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $47.00 per share in cash, representing a 26% premium to its unaffected 20-day volume-weighted average price.

Merck KGaA, Darmstadt, Germany, will acquire SpringWorks Therapeutics for $47.00 per share in cash, pending shareholder and regulatory approval, expected to close in the second half of 2025.

Merck KGaA, Darmstadt, Germany, will acquire SpringWorks Therapeutics for $47 per share in cash, a deal valued at approximately $3.9 billion, to bolster its healthcare business and expand its presence in the rare tumor treatment market.

SpringWorks Therapeutics will hold its annual stockholder meeting virtually on May 14, 2025, to vote on director elections, auditor ratification, and executive compensation.

SpringWorks Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 14, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.

SpringWorks Therapeutics will hold its annual stockholder meeting virtually on May 16, 2024, to vote on director election, auditor ratification, and executive compensation.

SpringWorks Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 16, 2024, to vote on director election, auditor ratification, and executive compensation.